Industry Active Role In Guidance Development Urged By Wyeth's Burlington
Regulated industry should take a more aggressive approach to writing guidances, Wyeth-Ayerst Senior VP-Global Regulatory Affairs Bruce Burlington, PhD, told a Parenteral Drugs Association/FDA joint conference Sept. 29 in Bethesda, Md.
You may also be interested in...
FDA should get input from industry before the release of draft guidances, the Pharmaceutical Research & Manufacturers of America suggests in comments to FDA on the implementation of good guidance practice provisions included in the FDA Modernization Act.
The Pharmaceutical Research & Manufacturers of America Health Outcomes Working Group is compiling health-related quality of life measurement recommendations in a report for industry.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011